DEA Finalizes Cannabis Schedule III Reclassification Order

The Drug Enforcement Administration has issued its final administrative order reclassifying marijuana from Schedule I to Schedule III under the Controlled Substances Act, completing a regulatory process that began with the Biden administration's directive in October 2022. The rescheduling takes effect 60 days after publication in the Federal Register, marking the first time cannabis classification has changed since the drug war era.

The reclassification creates immediate tax advantages for state-licensed cannabis operators, eliminating the punitive 280E tax provision that has prevented marijuana businesses from deducting standard operating expenses. Multi-state operators like Curaleaf Holdings (CURLF), Green Thumb Industries (GTBIF), and Trulieve Cannabis (TCNNF) stand to benefit from substantially improved profit margins as they gain access to normal business deductions for rent, salaries, and marketing costs.

Schedule III status enables legitimate medical research into cannabis compounds and therapeutic applications, potentially accelerating pharmaceutical development programs. However, the rescheduling does not legalize recreational marijuana at the federal level or resolve the banking restrictions that force most cannabis companies to operate as cash-only businesses. State-licensed dispensaries and cultivation facilities remain federally illegal outside medical contexts.

The cannabis industry faces continued regulatory uncertainty as the incoming Trump administration may reverse or modify the rescheduling decision. Previous statements from Trump officials suggest a more restrictive approach to federal cannabis policy, creating potential headwinds for operators who have invested heavily in expansion plans based on improved regulatory conditions.

Investors should expect increased volatility in cannabis equity markets as companies adjust business models and financial projections around the new tax structure. The rescheduling represents progress toward normalization but falls short of the comprehensive reform that would unlock institutional investment and interstate commerce opportunities that could drive the next phase of industry consolidation.